loader2
Partner With Us NRI

Krsnaa Diagnostics Ltd share Price Today

Company details

825.00
865.00
528.05
880.60
6M Return 31.67%
1Y Return 30.60%
Mkt Cap.(Cr) 2,677.00
Volume 1,42,255
Div Yield 0.30%
OI
-
OI Chg %
-
Volume 1,42,255

Invest in Market with Confidence: High performance strike rate of over 72%

Trade, sell, withdraw – all in minutes!
icon 27 Years

of legacy

icon 4.4 Star

App Rating

icon 1 Crore +

Customers

Open a Trading Account

Achieve your Investment goals today!

+91
Please enter valid Mobile Number

Healthcare Services company Krsnaa Diagnostics announced Q1FY25 results:

Financial Highlights: 

  • Revenue from Operations: Rs 1,702 million in Q1FY25, a 22% increase compared to Rs 1,396 million in Q1FY24 and a 2% increase from Rs 1,663 million in Q4FY24.
  • Other Income: Rs 73 million in Q1FY25, showing a 43% increase compared to Rs 42 million in Q1FY24.
  • Total Income: Rs 1,775 million in Q1FY25, a 23% increase from Rs 1,438 million in Q1FY24 and a 4% increase from Rs 1,706 million in Q4FY24.
  • EBITDA: Rs 442 million in Q1FY25, a 39% increase from Rs 319 million in Q1FY24, and virtually unchanged from Rs 445 million in Q4FY24.
  • EBITDA Margin: 26% in Q1FY25, up from 23% in Q1FY24 but down from 27% in Q4FY24.
  • EBIT: Rs 285 million in Q1FY25, a 44% increase compared to Rs 199 million in Q1FY24, and a 4% decrease from Rs 299 million in Q4FY24.
  • EBIT Margin: 16% in Q1FY25, improved from 14% in Q1FY24 but down from 18% in Q4FY24.
  • Profit After Tax (PAT): Rs 179 million in Q1FY25, representing a 24% increase from Rs 146 million in Q1FY24 and a 4% decrease from Rs 187 million in Q4FY24.
  • PAT Margin: 11% in Q1FY25, consistent with the margin in Q1FY24 and Q4FY24.
  • Reported Diluted EPS: Rs 5.46 in Q1FY25, compared to Rs 4.52 in Q1FY24 and Rs 5.70 in Q4FY24.

Operational Highlights:

  • Krsnaa has bagged the contract for Tele-Radiology from BARC
  • Krsnaa has signed an agreement for 5 MRIs to be installed in 5 districts of Madhya Pradesh
  • Krsnaa has Launched Krsnaa Retail Pvt. Ltd to focus on increasing their retail presence beginning with 5 states i.e. Maharashtra, Punjab, Odisha, Assam & Himachal Pradesh.
  • Krsnaa expanded its presence by establishing 395 new centers across the nation.

Commenting on the results, Yash Mutha, Joint Managing Director, said: “Krsnaa's exceptional service offerings, characterized by competitive pricing, have played a pivotal role in driving patient and test counts.

We are committed to enhancing the customer experience by offering exceptional healthcare solutions customized to individual needs. Krsnaa has established itself as a prominent player in the PPP sector and is one of the largest in the industry. Given the industry's growth and the next phase for our organization, we believe it is the right time to venture into the retail space. Our strategy is to offer a wide range of services to the general population, starting with states where we already have wellestablished lab and radiology centers through our PPP contracts. This approach will help us increase our margins and shorten our working capital cycle.

During the initial quarter of FY2025, Krsnaa accomplished a notable 22% increase compared to the previous year, leading to revenues totalling Rs. 1,702 million. Our EBIDTA reached Rs. 442 million with a 26% margin, and the net profit was Rs. 179 million with an 11% margin. This progress can be credited to our status as the government's preferred partner, heightened recognition of Krsnaa as a brand, maintaining high-quality services, and the successful and punctual execution of our projects.

We are also working on various other PAN India tenders, which will be announced once there is more clarity from the respective departments. At the gateway of boundless potential, we are unwavering in our commitment to adjust, create, and thrive. We have developed ambitious strategies to discover chances for progress and development, guaranteeing that we persist in positively influencing lives and contributing to the advancement of the healthcare sector.”

Commenting on the Business, Pallavi Bhatevara, Executive Director said: “Our company is well positioned to take advantage of the changes in the diagnostic industry, especially with the government's emphasis on delivering high-quality healthcare to all citizens. The budget for the National Health Mission (NHM) for 2024-25 is set at Rs 38,183 crores, marking a significant rise from the revised allocation of Rs 33,886 crores in 2023-24.

Krsnaa diagnostics limited continues to play a major role in providing high-quality and affordable diagnostic services. The provision of high-quality and affordable diagnostic services stands as a fundamental pillar within the healthcare industry. It is with great pleasure that I announce our successful execution of an agreement for the Madhya Pradesh Radiology tender, a significant opportunity that encompasses 5 MRI centre, along with these we have also bagged a contract for Tele-radiology from BARC. These showcase our capabilities and strength to grow in diagnostic industry.

Currently, Krsnaa Diagnostics is well-equipped to deploy 28 CT scan machines, 24 MRI machines, establish 153 labs, and set up 2,291 collection centers, all under various contractual agreements. The recent contract wins highlight the exceptional capabilities of our in-house teams. It reflects their proficiency in navigating the intricate bidding process, meeting all necessary requirements, and ultimately securing these contracts. As we begin these projects, Krsnaa Diagnostics is actively expanding its presence into new geographical regions, laying a strong foundation for sustainable, long-term growth.”

Result PDF

View Other Company Results

Krsnaa Diagnostics Ltd shares SWOT Analysis

Strengths (7)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Good quarterly growth in the recent results
  • Company with Low Debt

Weakness (5)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (1)

  • RSI indicating price strength

Threats (3)

  • High PE (PE > 40)
  • Red Flag: Resignation of Top Management
  • Increasing Trend in Non-Core Income

Resistance and support

R1 854.4
R2 879.7
R3 894.4
Pivot

839.68

S1 814.4
S2 799.7
S3 774.4
EMA SMA
803.5
747.9
704.4
669.3
796.6
731.3
673.6
666.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
KITARA PIIN 1104 Bulk Sell 2024-06-12 600.69 372000 NSE
EAST LANE CAPITAL LLP Block Purchase 2023-10-03 675 150000 NSE
MEDIMAZE SOLUTIONS PRIVATE LIMITED Block Sell 2023-10-03 675 150000 NSE
Name Category Shares
RAJENDRA KHIVRAJ MUTHA PROMOTER 24.87%
KRSNA DIAGNOSTICS (MUMBAI) PRIVATE LIMITED PROMOTER 2.3%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Krsnaa Diagnostics Ltd Stocks COMPARISON

Financials( in Cr) Krsnaa Diagnostics Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Fortis Healthcare Ltd Syngene International Ltd
Price 829.05 7,234.00 994.75 596.70 884.15
% Change -2.79 1.57 -3.46 0.29 -1.13
Mcap Cr 2,677.00 1,04,014.07 96,680.95 45,048.34 35,590.31
Revenue TTM Cr 619.63 7,273.80 5,704.20 7,175.67 3,488.60
Net Profit TTM Cr 56.84 1,010.50 1,057.64 645.22 510.00
PE TTM 44.54 100.47 91.82 70.38 74.70
1 Year Return 30.60 41.93 78.86 79.62 14.82
ROCE 9.62 15.48 14.96 9.65 13.56
ROE 7.34 13.81 13.37 7.81 12.95
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 809.81 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 17,492.71 71,886.12
LAST 3M 78,204.11 61,813.64
LAST 6M 1,87,352.46 86,996.15
LAST 12M 3,32,953.72 1,53,700.57
Krsnaa Diagnostics Limited - Shareholders meeting

Sep 24, 2024 l NSE Announcement

Krsnaa Diagnostics Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Sep 23, 2024 l NSE Announcement

Date Action Type Ratio
Sep 13, 2024 Dividend 50
Sep 15, 2023 Dividend 55
Sep 15, 2022 Dividend 50

Krsnaa Diagnostics Ltd Information

Stock PE (TTM)
44.54
Promoter Holding
27.17%
Book Value
250.7921
ROCE
9.62%
ROE
7.34%
Description
  • Krsnaa Diagnostics Limited was originally incorporated as `Krsna Diagnostics Private Limited` at Pune, Maharashtra dated December 22, 2010. The Company name was changed to `Krsnaa Diagnostics Private Limited`, pursuant to a fresh Certificate of Incorporation issued by the RoC on January 29, 2015. Thereafter, the status got converted into a Public Company and the name was changed to Krsnaa Diagnostics Limited pursuant to a fresh Certificate of Incorporation issued by the RoC on 06 May, 2021. The Company is primarily engaged in providing diagnostic services centres all over India. The company is providing Radiology and Pathology services for X-ray, CT Scan, MRI, Mammography, Tele-Reporting services, all type of blood and urine investigation and other related diagnostic services. The Company owns an extensive network of integrated diagnostics centres across India primarily in non-metro and lower-tier cities and towns, with operating 1823 diagnostics centres offering radiology and pathology services in 13 states across the country. The Company started operating 12 centres in Himachal Pradesh in public private partnership during the period 2012. It installed 50 centres in 4 states in 2017 and expanded operations across 13 states in 2018. Further, it expanded the operations to over 1500 centres across India in 2020. The Company in August 2021, came up with an Initial Public Offer of 12,741,036 Equity Shares by raising funds from public aggregating to Rs.1213.33 Crore, comprising a Fresh Issue of 4,215,516 Equity Shares aggregating to Rs 400 Crore and an Offer for Sale of 8,525,520 Equity Shares aggregating to Rs. 813.33 Crore. The Company operationalized 26 radiology centers, 50 pathology labs, and 556 collection centers in 2022-23. It expanded geographical presence from 660 centers in FY 2018 to over 2,800 centers in FY 2023. The Teleradiology hub in Pune achieved prestigious accreditation from the National Accreditation Board for Hospitals & Healthcare Providers (NABH) during the year 2023. The Company expanded its geographical presence to more than 3600 centres in FY 2024.

No Data Found

AGM Date (Month) : Jul
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 543328
NSE Code : KRSNAA
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE08LI01020

FAQ’s on Krsnaa Diagnostics Ltd Shares

You can buy Krsnaa Diagnostics Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Krsnaa Diagnostics Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 27, 2024 04:00 PM the closing price of Krsnaa Diagnostics Ltd was Rs.829.05.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 27, 2024 04:00 PM, the market cap of Krsnaa Diagnostics Ltd stood at Rs. 2,677.00 Cr.

The latest PE ratio of Krsnaa Diagnostics Ltd as of Sep 27, 2024 04:00 PM is 44.54

The latest PB ratio of Krsnaa Diagnostics Ltd as of Sep 27, 2024 04:00 PM is 0.30

The 52-week high of Krsnaa Diagnostics Ltd share price is Rs. 880.60 while the 52-week low is Rs. 528.05

According to analyst recommendations, Krsnaa Diagnostics Ltd Share has a "" rating for the long term.

Download App

Download Our App

Play Store App Store
market app

Open a Trading Account

Achieve your Investment goals today!

+91
Please enter valid Mobile Number